SR9009 (Stenabolic)

Overview

SR9009, commonly referred to as Stenabolic, is a synthetic Rev-Erb agonist developed by Professor Thomas Burris and colleagues at the Scripps Research Institute. First described in a 2012 publication in Nature Medicine, the compound targets the nuclear receptors Rev-Erb-alpha and Rev-Erb-beta, which function as key regulators of the circadian clock and metabolism. SR9009 is not a SARM and does not interact with the androgen receptor, though it is frequently grouped with SARMs in commercial and online contexts due to its performance-related effects and similar distribution channels.

The Rev-Erb receptors are constitutive transcriptional repressors that play central roles in synchronizing metabolic processes with the circadian cycle. By activating these receptors, SR9009 effectively rewires cellular metabolism, increasing mitochondrial activity, boosting fatty acid oxidation, and modulating inflammatory pathways. The original research demonstrated striking metabolic effects in mouse models, including increased endurance, reduced body fat, and favorable changes in cholesterol and triglyceride levels, all without changes in food intake or physical activity.

Mechanism of Action

SR9009 binds to and activates the Rev-Erb-alpha and Rev-Erb-beta nuclear receptors. These receptors function as ligand-sensitive transcriptional repressors, meaning that their activation leads to the suppression (rather than induction) of target gene expression. The genes repressed by Rev-Erb activation are critically involved in gluconeogenesis, lipogenesis, inflammatory cytokine production, and the core circadian clock machinery itself.

In skeletal muscle, Rev-Erb activation by SR9009 increases mitochondrial content and oxidative capacity. The compound upregulates genes involved in mitochondrial biogenesis and fatty acid oxidation while repressing genes that promote fat storage. This metabolic reprogramming shifts the balance of energy utilization toward oxidative metabolism, producing effects that mimic the metabolic adaptations normally achieved through endurance exercise training.

In the liver, SR9009 suppresses lipogenic gene expression and reduces de novo lipogenesis, contributing to improvements in dyslipidemia and hepatic steatosis. In macrophages and other immune cells, the compound suppresses inflammatory gene expression, reducing the production of IL-6 and other pro-inflammatory cytokines. This anti-inflammatory effect has attracted interest in the context of chronic inflammatory conditions and metabolic syndrome.

A critical feature of Rev-Erb biology is its role in the circadian clock. Rev-Erb-alpha is a core component of the molecular clock, and its pharmacological activation by SR9009 alters circadian gene expression patterns. In animal studies, SR9009 administration modified the expression of clock genes including Bmal1, Cry1, and Per2. The physiological consequences of this circadian modulation in the context of long-term compound use are not fully understood.

Research Summary

The foundational study by Solt et al. (2012) in Nature Medicine demonstrated that SR9009 administration to diet-induced obese mice for 12 days reduced body fat by 5%, decreased plasma triglycerides by 12%, decreased total cholesterol by 47%, and increased running endurance by approximately 50%. These effects occurred without changes in food intake, ruling out appetite suppression as the mechanism. The metabolic improvements were attributed to increased energy expenditure through enhanced mitochondrial activity.

Subsequent studies from the Burris laboratory and other groups expanded on these findings. SR9009 was shown to reduce anxiety-like behavior in mice, potentially through its effects on circadian-regulated neurochemical pathways. The compound also demonstrated antitumor activity in several cancer cell lines, with cytotoxic effects attributed to disruption of circadian clock regulation in malignant cells, which rely heavily on clock gene expression for survival signaling.

Research into cardiac applications showed that SR9009 reduced cardiac hypertrophy and fibrosis in mouse models of heart disease. In a transverse aortic constriction model, the compound attenuated pathological cardiac remodeling and preserved cardiac function. These findings suggested potential therapeutic applications in heart failure, though the work has not advanced beyond preclinical investigation.

A significant pharmacological limitation emerged from bioavailability studies. SR9009 has very poor oral bioavailability in rodents, estimated at less than 2% in some reports. Many of the published studies administered the compound via intraperitoneal injection, raising questions about whether oral administration (the route used by most research community participants) can achieve systemic levels sufficient to reproduce the published effects. This bioavailability concern is a major point of scientific debate surrounding the compound.

Dosing in Published Research

SR9009 (stenabolic) is a synthetic agonist of the REV-ERB proteins, developed as a laboratory research tool. It has not been studied in any human clinical trial of any phase, so no controlled research has established a dose for it in people; additionally, SR9009 has very poor oral bioavailability, which limits its relevance as an oral compound. Specific figures circulating in forums or vendor material are not derived from human research and are therefore not reported here.

Safety and Side Effects

The safety profile of SR9009 is minimally characterized. No human clinical trials have been conducted, and formal toxicology studies have not been published. The compound does not interact with the androgen receptor, meaning it does not suppress endogenous testosterone production or produce androgenic side effects. This is a meaningful distinction from SARMs and represents one of the compound’s most frequently cited advantages.

Because Rev-Erb activation alters circadian clock gene expression, theoretical concerns exist regarding disruption of normal circadian rhythms with chronic use. The circadian clock regulates a vast array of physiological processes, including sleep-wake cycles, hormone secretion, immune function, and cellular repair. Sustained pharmacological manipulation of this system could produce unpredictable downstream effects, though no specific adverse circadian-related outcomes have been identified in the available preclinical data.

User reports from the research community describe relatively few acute side effects, though the poor oral bioavailability means that many users may not be achieving significant systemic exposure through oral dosing. Reported effects are generally mild and include wakefulness (potentially reflecting circadian modulation), mild headache, and in some cases, difficulty sleeping if the compound is taken later in the day. No consistent hepatotoxicity signals have been reported in user bloodwork.

The absence of HPG axis suppression means that SR9009 does not require post-cycle therapy, which distinguishes it from SARMs and anabolic compounds in terms of the hormonal recovery burden on users.

Current Research Status

SR9009 is a preclinical research compound with no clinical development program and no approved medical indications. It is not currently listed as a prohibited substance by WADA under the SARM category, though it could potentially be classified under the category of metabolic modulators. Academic research on Rev-Erb biology continues to expand, with SR9009 serving as the primary pharmacological tool for studying these receptors. The oral bioavailability limitation has spurred interest in next-generation Rev-Erb agonists with improved drug-like properties. The compound remains available through research chemical suppliers, though the gap between the injectable administration used in published research and the oral route used by most consumers is a significant and unresolved question.

Frequently Asked Questions